Krystal Biotech, Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Krystal Biotech, Inc. (KRYS) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$3.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-03
- Krystal Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$1.33M, a 878.36% decline year-over-year.
- Krystal Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $171.00K, a 8.56% decline year-over-year.
- Krystal Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was $187.00K.
- Krystal Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$36.00K.
- Krystal Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $286.00K.
- Krystal Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$458.00K.
- Krystal Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$156.00K.
- Krystal Biotech, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$41.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.16M 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | -$1.33M 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $286.00K 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $923.00K 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $1.23M 10-Q · filed 2026-08-03 | |||
| 2025-03-31 | $171.00K 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | -$458.00K 10-K · filed 2026-02-17 | |||
| 2024-09-30 | $136.00K 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | -$150.00K 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | $187.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | -$156.00K 10-K · filed 2026-02-17 | |||
| 2023-09-30 | -$16.00K 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | -$28.00K 10-Q · filed 2024-08-05 | |||
| 2023-03-31 | -$36.00K 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | -$41.00K 10-K · filed 2025-02-19 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-26 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |